Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/9b28bb1b-fbed-4a0d-ab4e-4c92c92d9dc0/

NGEN

NervGen Pharma Corp.
Chart
1.67 USD
Latest Week 2026-07-17
HealthcareBiotechnologyMICRO
Snapshot 2026-07-19 · 0.6w · Fresh
0.47
OS Score
48.0%
Value
46.0%
Quality
47.0%
Momentum
3/9
F-Score
0.470
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
0 of 23 passing
★
OS Composite
✗
↗
Trending Value
✗
◆
Quality × Value
✗
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
✗
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
✗
🌱
GARP
✗
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
✗
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
✗
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
48.0%ile
P/B
32.1×
FCF Yield
-0.170
SH Yield
-0.095
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
53.00000000
/100 — 1=cheapest
VC2 (Trending Value)
53.00000000
/100
VC3 (Buyback)
54.00000000
/100
Negative FCF yield (-17.0%) — the business is currently cash-consumptive.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
46.0%ile
ROE
-8.436
ROA
-2.251
GPA
-0.001
D/E
2.75
Current
1.34
F-Score
3/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Stability
1.052
lower=better
Accruals
-0.927
lower=better
5yr Consist
No
Highly leveraged with D/E of 2.75 — returns are being amplified by debt.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
47.0%ile
6M Return
-70.3%
Vol 252d
86.4%
Vol 60d
105.9%
↑ Expanding
Max DD 12M
-71.0%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
OS
Composite & Factor Heatmap
All factors at a glance
0.47
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 500 peers
Sector Value %ile
23.4%
Sector Quality %ile
17.8%
P/B z-score
1.25
Sector Avg OS
64.1%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
FBIOP Fortress Biotech Inc Pref Series A 99.0% 98.0% 84.0% 96.0%
IRWD Ironwood Pharmaceuticals Inc 99.0% 92.0% 91.0% 98.0%
CGEN Compugen 98.0% 89.0% 96.0% 82.0%
RIGL Rigel Pharmaceuticals Inc 98.0% 90.0% 93.0% 93.0%
FBIO Fortress Biotech Inc 98.0% 98.0% 84.0% 88.0%
NUTX Nutex Health Inc 98.0% 91.0% 98.0% 80.0%
TBPH Theravance Biopharma Inc 98.0% 90.0% 99.0% 84.0%
MD Mednax Inc 97.0% 85.0% 84.0% 93.0%
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
F
0.0% avg (3 factors)
Quality
F
27.5% avg (6 factors)
Momentum
F
0.0% avg (1 factors)
Risk
F
0.0% avg (1 factors)
Momentum is weak, suggesting the market isn't yet buying this thesis. Patience required. Elevated risk profile — position sizing should reflect the higher volatility.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Score Trends7 snapshots
Factor Persistence7 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.470—0—
Value %ile0.480—0—
Quality %ile0.460—0—
Momentum %ile0.470—0—
F-Score3.000—7—
Confidence0.558—0—
Volatility0.864—7—
Value Lens2021-07-20 → 2026-07-19
P/E Ratio
Earnings Yield
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
Price / Book
32.09
FCF Yield
-17.0%
Shareholder Yield
Div + net buyback / mktcap
-9.5%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
-843.6%
Return on Assets
-225.1%
Gross Profit / Assets
Novy-Marx GPA
-0.1%
Debt / Equity
2.75
Current Ratio
1.34
Accruals Ratio
(NI-OCF)/Assets — lower=better
-0.927
MomentumPrice trend strength over different horizons
6M Return
-70.3%
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Earnings Stability (CV)
Lower = more stable
1.052
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
3
Buyback Yield
-9.5%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
53
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
53
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
54
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity